The September/October issue of NeuroPerspective features our annual, epic, and comprehensive review of the Alzheimer’s space, including a review of the current thinking around pathophysiology and therapeutic targets:An updated assessment on the roles of amyloid, tau, neuroinflammation, and other targets is included. The subtitle for the review is ‘Reset, Reboot,Recalibrate’, because the traditional modus operandi for the Industry in its approach to AD has produced little beyond a series of dispiriting failures and mediocre demi-signals.
Among the 150+ programs are assessed are those from: AbbVie, AB Science, AC Immune, AgeneBio, Allergan, Alkahest, Anavex, Asceneuron, AstraZeneca, Axon-Neuroscience, Axovant, Biogen, Cognition Therapeutics, Cortexyme, Denali, Eisai, E-Scape, Genentech, Intra-Cellular, JNJ, Karuna, Lilly, Lundbeck, Merck, Novartis, Oryzon, Pfizer, Prana, Probiodrug, Proclara, ProMIS, Roce, Takeda, TauRx, Tetra Drug Discovery, United Neuroscience, and Voyager. Alkahest is the focus of the Company Review, sidebars include coverage of the current state of the AD Biomarker art and a consideration of the POC timelines for major AD programs.
The Sept/Oct issue also includes a full review of ADHD, including the search for nonstimulant options that might approach the efficacy of the psychostimulants. Programs from Aevi, Alcobra, NLS Pharma, Otsuka/Neurovance, Sunovion, and Supernus are among those assessed in the review.
75 pages.
Read More
